Last 12 months
Inside the activity.
4 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 3 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 14, 2026 21:30 UTC |
Violette Shelia M.Chief Scientific Officer
|
SaleCommon Stock | 917 | $8.32 | $7,629.16 |
DisclosureSEC source: 0001193125-26-421835 · ownership.xml · nonDerivative · entry 1 Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,854 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.07 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 06, 2026 Filed Oct 14, 2026 21:30 UTC |
Morrison Jodie PopeDirector · CEO
|
SaleCommon Stock | 3,221 | $8.32 | $26,798.08 |
DisclosureSEC source: 0001193125-26-421836 · ownership.xml · nonDerivative · entry 1 Morrison Jodie Pope · CIK 0001618247 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,038 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.08 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 06, 2026 Filed Oct 14, 2026 21:30 UTC |
Kalowski LeeCFO and President
|
SaleCommon Stock | 1,301 | $8.32 | $10,824.06 |
DisclosureSEC source: 0001193125-26-421834 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,170 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.08 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:10 UTC |
Violette Shelia M.Chief Scientific Officer
|
SaleCommon Stock | 2,798 | $16.56 | $46,334.88 |
DisclosureSEC source: 0001193125-26-371291 · ownership.xml · nonDerivative · entry 1 Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,771 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:10 UTC |
Kalowski LeeCFO and President
|
SaleCommon Stock | 3,972 | $16.56 | $65,776.32 |
DisclosureSEC source: 0001193125-26-371293 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,471 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:10 UTC |
Morrison Jodie PopeDirector · CEO
|
SaleCommon Stock | 9,845 | $16.56 | $163,033.20 |
DisclosureSEC source: 0001193125-26-371292 · ownership.xml · nonDerivative · entry 1 Morrison Jodie Pope · CIK 0001618247 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,259 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| July 16, 2026 Filed Jul 21, 2026 01:31 UTC |
Violette Shelia M.Chief Scientific Officer
|
GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-309331 · ownership.xml · nonDerivative · entry 1 Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,569 F1 · kind: Represents shares of Issuer common stock underlying performance-based restricted stock units ("PSUs") granted on July 6, 2026, which vested on July 16, 2026 with respect to a performance-based condition, upon achievement of the closing of a financing of at least $100,000,000 in gross proceeds on or before December 31, 2026. Such PSUs are also subject to a time-based condition, which provides that the PSUs shall vest in equal quarterly installments over three years from July 1, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Each PSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 16, 2026 Filed Jul 21, 2026 01:25 UTC |
Kalowski LeeCFO and President
|
GrantCommon Stock | 53,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-309324 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,443 F1 · kind: Represents shares of Issuer common stock underlying performance-based restricted stock units ("PSUs") granted on July 6, 2026, which vested on July 16, 2026 with respect to a performance-based condition, upon achievement of the closing of a financing of at least $100,000,000 in gross proceeds on or before December 31, 2026. Such PSUs are also subject to a time-based condition, which provides that the PSUs shall vest in equal quarterly installments over three years from July 1, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Each PSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 16, 2026 Filed Jul 21, 2026 01:27 UTC |
Morrison Jodie PopeDirector · CEO
|
GrantCommon Stock | 132,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-309327 · ownership.xml · nonDerivative · entry 1 Morrison Jodie Pope · CIK 0001618247 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,104 F1 · kind: Represents shares of Issuer common stock underlying performance-based restricted stock units ("PSUs") granted on July 6, 2026, which vested on July 16, 2026 with respect to a performance-based condition, upon achievement of the closing of a financing of at least $100,000,000 in gross proceeds on or before December 31, 2026. Such PSUs are also subject to a time-based condition, which provides that the PSUs shall vest in equal quarterly installments over three years from July 1, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Each PSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:30 UTC |
Manke IsaacDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-26-294694 · ownership.xml · derivative · entry 2 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:30 UTC |
Manke IsaacDirector
|
Exercise / conversionCommon Stock | 53,521 | $2.80 | $149,858.80 |
DisclosureSEC source: 0001193125-26-294694 · ownership.xml · nonDerivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:30 UTC |
LAPORTE KATHLEENDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-272701 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:30 UTC |
Manke IsaacDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-272698 · ownership.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:30 UTC |
Iwicki Mark TDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-272700 · ownership.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:30 UTC |
Thistle MaryDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-272690 · ownership.xml · derivative · entry 1 Thistle Mary · CIK 0001317917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:30 UTC |
TZIANABOS ARTHURDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-272697 · ownership.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:30 UTC |
GRAYZEL DAVID S.Director
|
GrantStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-272692 · ownership.xml · derivative · entry 1 GRAYZEL DAVID S. · CIK 0001732786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:30 UTC |
Xu DiyongDirector · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-272686 · ownership.xml · derivative · entry 1 Xu Diyong · CIK 0001995088 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F2 · ownership.direct: Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:30 UTC |
Lundberg Sven AnteDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-272684 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 12, 2026 Filed Jul 22, 2026 00:39 UTC Amendment |
LAPORTE KATHLEENDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,826 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-310980 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. Read SEC document |
| June 12, 2026 Filed Jul 22, 2026 00:25 UTC Amendment |
Manke IsaacDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,826 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-310969 · ownership.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. Read SEC document |
| June 12, 2026 Filed Jul 22, 2026 00:37 UTC Amendment |
Iwicki Mark TDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,826 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-310978 · ownership.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. Read SEC document |
| June 12, 2026 Filed Jul 22, 2026 00:22 UTC Amendment |
Thistle MaryDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,826 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-310965 · ownership.xml · derivative · entry 1 Thistle Mary · CIK 0001317917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. Read SEC document |
| June 12, 2026 Filed Jul 22, 2026 00:40 UTC Amendment |
TZIANABOS ARTHURDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,826 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-310983 · ownership.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. Read SEC document |
| June 12, 2026 Filed Jul 22, 2026 00:39 UTC Amendment |
Lundberg Sven AnteDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,826 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-310982 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. Read SEC document |
| June 12, 2026 Filed Jul 22, 2026 00:25 UTC Amendment |
Xu DiyongDirector · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 10,826 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-310970 · ownership.xml · derivative · entry 1 Xu Diyong · CIK 0001995088 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F3 · ownership.direct: Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP. Read SEC document |
| June 12, 2026 Filed Jul 22, 2026 00:24 UTC Amendment |
GRAYZEL DAVID S.Director
|
GrantStock Option (Right to Buy) · Derivative | 10,826 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-310967 · ownership.xml · derivative · entry 1 GRAYZEL DAVID S. · CIK 0001732786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F3 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 28, 2026 Filed Jun 2, 2026 01:13 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VII LLCDirector · 10% owner
OrbiMed Genesis GP LLCDirector · 10% owner
|
PurchaseCommon Stock | 625,000 | $8.00 | $5,000,000.00 |
DisclosureSEC source: 0000947871-26-000593 · ownership.xml · nonDerivative · entry 2 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VII LLC · CIK 0001760648 · Director · 10% owner OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 625,000 F1 · shares: These shares of the Issuer's common stock were purchased from the Issuer in a private placement. F3 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Diyong Xu, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| May 28, 2026 Filed Jun 2, 2026 01:13 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VII LLCDirector · 10% owner
OrbiMed Genesis GP LLCDirector · 10% owner
|
PurchaseCommon Stock | 1,250,000 | $8.00 | $10,000,000.00 |
DisclosureSEC source: 0000947871-26-000593 · ownership.xml · nonDerivative · entry 1 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VII LLC · CIK 0001760648 · Director · 10% owner OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,502,987 F1 · shares: These shares of the Issuer's common stock were purchased from the Issuer in a private placement. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Diyong Xu, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| May 28, 2026 Filed Jun 2, 2026 01:15 UTC |
Xu DiyongDirector · 10% owner
|
PurchaseCommon Stock | 625,000 | $8.00 | $5,000,000.00 |
DisclosureSEC source: 0000947871-26-000594 · ownership.xml · nonDerivative · entry 2 Xu Diyong · CIK 0001995088 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 625,000 F1 · shares: These shares of the Issuer's common stock were purchased from the Issuer in a private placement. F3 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis. F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, OrbiMed GP, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| May 28, 2026 Filed Jun 2, 2026 01:15 UTC |
Xu DiyongDirector · 10% owner
|
PurchaseCommon Stock | 1,250,000 | $8.00 | $10,000,000.00 |
DisclosureSEC source: 0000947871-26-000594 · ownership.xml · nonDerivative · entry 1 Xu Diyong · CIK 0001995088 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,502,987 F1 · shares: These shares of the Issuer's common stock were purchased from the Issuer in a private placement. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII. F4 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, OrbiMed GP, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| February 25, 2026 Filed Feb 28, 2026 00:00 UTC |
Violette Shelia M.Chief Scientific Officer
|
SaleCommon Stock | 2,815 | $4.51 | $12,708.04 |
DisclosureSEC source: 0001193125-26-083584 · ownership.xml · nonDerivative · entry 1 Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,569 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 25, 2026 Filed Feb 28, 2026 00:00 UTC |
Kalowski LeeCFO and President
|
SaleCommon Stock | 3,995 | $4.51 | $18,035.03 |
DisclosureSEC source: 0001193125-26-083588 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,943 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 25, 2026 Filed Feb 28, 2026 00:00 UTC |
Morrison Jodie PopeDirector · CEO
|
SaleCommon Stock | 9,896 | $4.51 | $44,674.50 |
DisclosureSEC source: 0001193125-26-083585 · ownership.xml · nonDerivative · entry 1 Morrison Jodie Pope · CIK 0001618247 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,104 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 24, 2026 Filed Mar 20, 2026 23:00 UTC |
Violette Shelia M.Chief Scientific Officer
|
GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-118054 · ownership.xml · nonDerivative · entry 1 Violette Shelia M. · CIK 0002016144 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,069 F1 · kind: The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 24, 2026 Filed Mar 20, 2026 23:00 UTC |
Kalowski LeeCFO and President
|
GrantCommon Stock | 53,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-118052 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,193 F1 · kind: The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 24, 2026 Filed Mar 20, 2026 23:00 UTC |
Morrison Jodie PopeDirector · CEO
|
GrantCommon Stock | 132,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-118053 · ownership.xml · nonDerivative · entry 1 Morrison Jodie Pope · CIK 0001618247 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,104 F1 · kind: The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 15, 2026 Filed Jan 31, 2026 00:00 UTC |
LAPORTE KATHLEENDirector
|
GrantStock Option (Right to Buy) · Derivative | 23,272 | $2.75 Strike: $3.60 | $63,998.00 |
DisclosureSEC source: 0001193125-26-032248 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,272 Underlying: Common Stock · 23,272 shares Expires 2036-01-14 F1 · price: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported. F1 · derivative.exercise_date: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported. Read SEC document |
| January 15, 2026 Filed Jan 31, 2026 00:00 UTC |
GRAYZEL DAVID S.Director
|
GrantStock Option (Right to Buy) · Derivative | 16,363 | $2.75 Strike: $3.60 | $44,998.25 |
DisclosureSEC source: 0001193125-26-032247 · ownership.xml · derivative · entry 1 GRAYZEL DAVID S. · CIK 0001732786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,363 Underlying: Common Stock · 16,363 shares Expires 2036-01-14 F1 · price: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported. F1 · derivative.exercise_date: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported. F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 15, 2026 Filed Jan 31, 2026 00:00 UTC |
Lundberg Sven AnteDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,363 | $2.75 Strike: $3.60 | $55,998.25 |
DisclosureSEC source: 0001193125-26-032246 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,363 Underlying: Common Stock · 20,363 shares Expires 2036-01-14 F1 · price: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported. F1 · derivative.exercise_date: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:00 UTC |
Kalowski LeeCFO and President
|
SaleCommon Stock | 9,072 | $3.46 | $31,395.47 |
DisclosureSEC source: 0001193125-25-308327 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,938 Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:00 UTC |
Morrison Jodie PopeDirector · CEO
|
SaleCommon Stock | 22,506 | $3.46 | $77,870.76 |
DisclosureSEC source: 0001193125-25-308328 · ownership.xml · nonDerivative · entry 1 Morrison Jodie Pope · CIK 0001618247 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,000 Read SEC document |
| October 23, 2025 Filed Oct 28, 2025 01:16 UTC |
LAPORTE KATHLEENDirector
|
GrantStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-25-251978 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 23, 2025 Filed Oct 28, 2025 01:26 UTC |
Manke IsaacDirector
|
GrantStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-25-251993 · ownership.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 23, 2025 Filed Oct 28, 2025 01:26 UTC |
Iwicki Mark TDirector
|
GrantStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-25-251994 · ownership.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 23, 2025 Filed Oct 28, 2025 01:19 UTC |
Thistle MaryDirector
|
GrantStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-25-251986 · ownership.xml · derivative · entry 1 Thistle Mary · CIK 0001317917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 23, 2025 Filed Oct 28, 2025 01:16 UTC |
TZIANABOS ARTHURDirector
|
GrantStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-25-251981 · ownership.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 23, 2025 Filed Oct 28, 2025 01:17 UTC |
GRAYZEL DAVID S.Director
|
GrantStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-25-251983 · ownership.xml · derivative · entry 1 GRAYZEL DAVID S. · CIK 0001732786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 23, 2025 Filed Oct 28, 2025 01:34 UTC |
Lundberg Sven AnteDirector
|
GrantStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-25-252000 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 23, 2025 Filed Oct 28, 2025 01:25 UTC |
Xu DiyongDirector
|
GrantStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-25-251992 · ownership.xml · derivative · entry 1 Xu Diyong · CIK 0001995088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F2 · ownership.direct: Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.